These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 32198651)

  • 1. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
    Babacan NA; Eroglu Z
    Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
    Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
    Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
    Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
    Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
    Swe T; Kim KB
    Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Therapies for Advanced Melanoma.
    Bomar L; Senithilnathan A; Ahn C
    Dermatol Clin; 2019 Oct; 37(4):409-423. PubMed ID: 31466582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.
    Haugh A; Daud AI
    Am J Clin Dermatol; 2024 May; 25(3):407-419. PubMed ID: 38329690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
    Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
    Front Immunol; 2021; 12():661737. PubMed ID: 34025662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
    Dulgar O; Kutuk T; Eroglu Z
    Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.
    Yu C; Liu X; Yang J; Zhang M; Jin H; Ma X; Shi H
    Front Immunol; 2019; 10():990. PubMed ID: 31134073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in managing metastatic melanoma: which treatment when?
    Amaral T; Meraz-Torres F; Garbe C
    Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
    Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous Complications of Targeted Melanoma Therapy.
    de Golian E; Kwong BY; Swetter SM; Pugliese SB
    Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan.
    Uhara H
    Int J Clin Oncol; 2019 Dec; 24(12):1508-1514. PubMed ID: 29470725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.
    Johnson DB; Pectasides E; Feld E; Ye F; Zhao S; Johnpulle R; Merritt R; McDermott DF; Puzanov I; Lawrence D; Sosman JA; Buchbinder E; Sullivan RJ
    J Immunother; 2017 Jan; 40(1):31-35. PubMed ID: 27846054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.
    Dixon-Douglas JR; Patel RP; Somasundram PM; McArthur GA
    Curr Oncol Rep; 2022 Aug; 24(8):1071-1079. PubMed ID: 35366166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.